Huateng Pharma Supplies PEG Products As Ingredients In mRNA COVID-19 Vaccines
What is an mRNA vaccine?
An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA (mRNA) to generate an immune response. Such vaccines deliver mRNA molecules into the body's immune cells, where they deliver a specific set of instructions to make protein fragments used by certain viruses. These protein molecules stimulate an adaptive immune response, teaching the body to recognize and destroy the corresponding viral attack. Using this technology, scientists have been experimenting with the potential use of mRNA for deadly diseases such as influenza, Ebola and SARS. Scientists have been experimenting with the use of mRNA therapy to develop personalized cancer treatments, as well as to develop vaccines against infectious diseases such as Zika virus. Scientists are also exploring whether mRNA therapy could be used as a protein replacement therapy for rare diseases such as the blood clotting disorder hemophilia.
mRNA vaccines have developed rapidly in the past two years of the epidemic, and the entire industry chain has now formed a behemoth, including incoming capital, production capacity in the hundreds of millions, and countless related workers.
But it is clear that there is only one product that supports this huge industrial chain - the new crown mRNA vaccine. But as per capita vaccination rates have increased, the market for mRNA vaccines for COVID-19 has declined in various expectations.
If mRNA doesn't find the next support point as soon as possible, it is actually difficult to maintain the "mRNA myth" by relying on the COVID-19 mRNA vaccine alone, so you can see that both Moderna and BioNTech are hurrying to carry out multi-party cooperation or develop new products by themselves.
When we talk about mRNA technology, we have to start with the central principle that DNA transports mRNA, and mRNA is translated into proteins, so as to achieve the cytoplasmic transmission of the genetic material of life.
In mRNA technology, mRNA that can encode a specific protein is delivered directly into human cells so that the cells translate the mRNA to express the target protein, either to activate the immune system's response to the protein (which is the mechanism of mRNA vaccines), or to replenish disease-causing proteins that the body lacks, and so on.
Since mRNA technology can enable cells to produce any information, it has a broad application prospect, including antiviral, tumor, protein deficiency/error diseases, and other types of diseases.
Virus vaccines & Tumor vaccines
In fact, mRNA technology is currently best known for its use in vaccines.
Based on the success of the COVID-19 mRNA vaccine, mRNA projects targeting various viral infections have also been launched, mostly based on the same basic principles.
Design mRNA that encodes viral fragments, and then inject them into the human body, so that cells produce viral proteins, thereby activating the human immune system to fight the virus and establish memory immunity to the disease. Once in the environment, the body is exposed to the virus, the body's immune system is activated again to fight the virus.
mRNA is in the direction of vaccines, in addition to antiviral vaccines, there is also a type of vaccine - tumor vaccines. However, compared with antiviral vaccines, the development of tumor vaccines is still relatively early (the leading echelon is generally in clinical phase 1), and there are more challenges to be solved.
First of all, the target problem of tumor vaccines is more eye-catching. Compared with the single target of virus vaccines, mRNA tumor vaccines usually encode twenty or thirty target proteins. This is also due to the variable target of mutation in tumor cells, while avoiding tumor target loss.
Secondly, mRNA tumor vaccines, as far as we currently understands, are mostly autologous products. This will also lead to a cost and price issue, which we will not discuss much, but can refer to CAR-T cell therapy.
In general, it is better to be optimistic about the next mRNA virus vaccine than to expect the overtaking of mRNA tumor vaccines.
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide range of incurable diseases. Under the assumption of mRNA therapy, many diseases can be treated.
Therapeutic applications include:
(1) Protein replacement to restore the function of a single protein for rare single-gene diseases;
(2) Cell reprogramming, mRNA can regulate cell behavior by expressing transcription or growth factors;
(3) Immunotherapy, in which mRNA-encoded transcripts elicit specific immune responses against target cells, such as therapeutic antibodies, to express virtually any desired protein in host cells and tissues and preserve host cell-intrinsic encoding Post-translational modification of proteins.
For mRNA therapy, low immunogenicity, high stability, and efficient translation are required by design. However, the expression of mRNA vaccines is transient and will degrade over time. Therefore, for chronic diseases, mRNA therapy is a long-term medication regimen.
Secondly, the delivery of mRNA is still dominated by lipid nanoparticles (LNPs). Lipid Nanoparticle (LNP) is currently the dominant delivery system. They are often used in vaccines due to their relatively easy uptake by antigen-presenting cells. The three major mRNA vaccine giants Moderna, CureVac and BioNTech are currently using LNP delivery technology for their COVID-19 vaccines. According to the current research reports, LNP technology is still insufficient and may have potential toxic and side effects. In addition, the current targeting of mRNA-LNPs is dominated by the liver, lung, and heart, and for other organs and cell types, new delivery technologies need to be developed.
In the field of mRNA therapy, CureVac Chief Financial Officer Pierre Kemula said in an interview that the eye may be a good breakthrough, with an independent treatment window and a safer dose.
mRNA gene editing
mRNA gene editing is also an emerging application of mRNA technology. Using mRNA to express Cas9 or other proteins in CRISPR gene editing technology can avoid the risks associated with the integration of nucleases into the host genome.
In this application area, the transient expression of mRNA becomes a unique advantage. The transient nature of mRNA expression limits intracellular nucleases, reducing the risk of off-target cleavage and immune responses to the Cas9 protein.
As a new pharmaceutical technology, mRNA has made breakthroughs in the treatment of infectious diseases and tumors in a short time. As a new technology, mRNA technology still has many areas to be developed, including various application areas and disease treatment. As science continues to advance, mRNA technology is expected to improve more disease treatments in the future.
As a professional PEG derivatives and pharmaceutical intermediates supplier, Huateng Pharma is able to provide high quality PEG products which used as ingredients in mRNA COVID-19 vaccines for your mRNA delivery from mg to kg.
Hunan Huateng Pharmaceutical Co. Ltd.
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818
Huateng Pharma is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on. We have a 34,000 square meter manufacturing site with advanced design concept of intelligent manufacturing, which can realize the integration of the production process and accomplish the complete transformation of lab scale - pilot plant - large-scale commercial production, with an annual capacity of more than 1 billion RMB.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Huateng Pharma Supplies PEG Products As Ingredients In mRNA COVID-19 Vaccines here
News-ID: 2715779 • Views: 326
More Releases from Hunan Huateng Pharmaceutical Co. Ltd.
Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and